A Phase 4 interventional study of Genotype guided P2Y12 therapy and Standard therapy group in Acute Coronary Syndromes (ACS), Unstable Angina Pectoris and Myocardial Infarction (MI), sponsored by Medisch Spectrum Twente. Not yet recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Medisch Spectrum Twente · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Acute Coronary Syndrome with a site in Netherlands — 15 open to participants now, 17 under way, none of them phase 3. Acute Coronary Syndrome · Netherlands.
Among the 86 studies in Acute Coronary Syndrome with a site in Netherlands, this one is the 23rd largest by planned enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2026, is one of 11 in phase 4, reaches primary completion later than 13 of the 16 other live ones, and was the 85th registered.
1,490 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →15 of the 86 studies in Acute Coronary Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:
Cyril Camaro · Sites in Netherlands
Ages 18+
Catharina Ziekenhuis Eindhoven · Sites in Netherlands
Ages 18+
Zuyderland Medisch Centrum · Sites in Netherlands
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 19 · Phase 4 11
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,120 is above the median of 200 across 867 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 1,811 across the 66 interventional studies, 2,209 across the 20 observational. Of the 57 that completed or were terminated, 21 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 86 have an industry lead sponsor. The 10 most frequent:
Medisch Spectrum Twente is the lead sponsor of 24 studies on the registry; 11 are open to participants now.
Medisch Spectrum Twente has 1 study filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Acute Coronary Syndrome with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06414187Erasmus Medical CenterClinical Effects of Intra-aortic Balloon Support in Early Acute Coronary Syndrome and Non-Acute Coronary Syndrome Related Cardiogenic Shock | 2027-06-01 |
| NCT04436978St. Antonius HospitalWhat is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies in Acute Coronary Syndrome with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rationale Patients diagnosed with acute coronary syndrome (ACS), a sudden medical emergency where blood flow to the heart is blocked, require dual antiplatelet therapy (DAPT) for 12 months to prevent dangerous blood clots to form. This typically includes the combination of aspirin and a form of P2Y12 inhibitor, a specific type of medicine that stops platelet cells to clot. Irrespective of the treatment strategy (i.e., invasive through angioplasty or conservative with medication only), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.
Although ischemic complications (problems that happen when the heart doesn't get enough blood and oxygen) usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. However, in 30% of the (white) European patients, there is a small change (mutation) in their genetic material. They are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate processing of clopidogrel in to its active form.
Despite knowledge of these loss of function mutations, current treatment guidelines for ACS do not provide specific recommendations on individualized, genotype-based treatment (i.e. using the unique genetic code to choose the medicine that works best) with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as they were too small and cautious to give definite answers.
Objective The goal of this clinical trial is to investigate whether individualized genotype-guided treatment with DAPT after ACS diagnosis is just as safe and effective as standard clinical practice.
Participants will receive:
Participants included in the genotype-guided group who do not carry a LOF allele will be classified as normal processors of clopidogrel, and will de-escalate after 30 days from standard therapy to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started.
Participants will be followed for 18 months after ACS diagnosis to collect medical data and to complete questionnaires.
Rationale Patients diagnosed with acute coronary syndrome (ACS) require dual antiplatelet therapy (DAPT) for 12 months. This typically includes aspirin and a P2Y12 inhibitor. Irrespective of the treatment strategy (i.e., invasive or conservative), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.
Although ischemic complications usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. Yet, in 30% of the (white) European patients are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate metabolization of clopidogrel.
Despite knowledge of these loss of function mutations, current ACS guidelines do not provide specific recommendations on individualized, genotype-based treatment with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as the conucted trials were underpowered due to sample size calculations based on ischemic endpoints, and the exclusion of ACS patients with high-risk features.
Objective
This randomized clinical trial aims to investigate whether individualized genotype-guided DAPT is non-inferior at 18 months follow-up to standard clinical practice of DAPT in all-comer patients with ACS with regard to:
Trial design This is a randomized, investigator-initiated, multicentre trial with 1:1 randomization of all-comer ACS patients for genotype-guided antiplatelet therapy, stratified for the presence of diabetes mellitus, sex and PCI.
Trial population All patients of 18 years or older with ACS, irrespective of the treatment strategy. If patients did not undergo a coronary angiography, there must be a history of coronary artery disease, proven myocardial defect by cardiac imaging that matches with previous MI, proven myocardial ischemia, or a known coronary obstruction ≥30% as previously visualized.
Interventions
If no major events (defined by NACE) occur during the first 30 days, patients will be randomly assigned (1:1) to:
Ethical considerations As both treatment strategies (i.e. aspirin plus clopidogrel or ticagrelor or prasugrel) are commonly used in treatment of ACS and considered standard care in Europe according to the ESC guidelines, no risks will be attached to treatment with any of the P2Y12 inhibitors. Patients who receive an individualized treatment strategy will possibly benefit from this, due to lower risk of bleeding complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients in whom no coronary angiography is performed during the index hospitalization or the first 30 days after the ACS, need to have at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dual antiplatelet therapy described at the cardiologist's discretion
Drug: Standard therapy group
Dual antiplatelet therapy based on CYP2C19 genotype. In case of normal or ultrafast metabolizer, patient will receive Clopidogrel 30-days after acute coronary syndrome. In case of proven carrier of the loss-of-function allele, patient will continue with ticagrelor.
Drug: Genotype guided P2Y12 therapy
All patients with ACS can be enrolled. Randomization will take place at time of ACS diagnosis. For the first 30 days after the index event, patients will be treated with DAPT as prescribed by the cardiologist. Patients who experience a major event (any death, spontaneous MI, definite stent thrombosis, any stroke, and major bleeding) during the first 30 days will be excluded from the main analysis. For these patients, DAPT treatment will remain unchanged. Included patients will be randomly assigned (1:1) to: 1. Standard treatment at the discretion of the cardiologist 2. Genotype-guided treatment In the patients randomized to the intervention arm genotyping will be performed and patients who do not carry a LOF allele will be classified as normal or ultrafast metabolizers. In these patients, de-escalation of P2Y12 inhibitor from standard therapy to clopidogrel will be performed around 30 days. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place.
Patients randomized for the standard therapy arm will receive dual antiplatelet therapy at the descretion of the cardiologist
Ischemic endpoint
Composition of cardiovascular death, myocardial infarction, definite stent thrombosis and ischemic stroke
Time frame: At 18 months follow-up
Net Adverse Cardiovascular Events
Composition of cardiovascular death, major bleeding, myocardial infarction, definite or probable stent thrombosis, and any stroke
Time frame: At 18 months follow-up
Adverse events
Death, Myocardial infarction, repeat revascularization, stroke, stent thrombosis, and bleeding
Time frame: At 18 months follow-up
Patient reported chest pain
Severity of chest pain by the Canadian Cardiovascular Society Angina Grade score classified into four classes (I to IV) based on the amount of exertion that triggers the symptoms. The higher the class, the lower the exercise tolerance.
Time frame: At 12- and 18-months follow-up
Patient reported dyspnea score
Prevalance and impact of dyspnea on patient's daily activities classified by the Medical Research Council Dyspnea Scale. There are 5 grades (0 to 4). The higher the grade, the greater the impact.
Time frame: At 12- and 18-months follow-up
Cost effectiveness analysis between the two treatment groups
Compare healthcare costs and health outcomes of the two treatment arms. Healthcare costs are determined by extracting healthcare utilization data from electronic health records and multiplying these resource-use frequencies by their corresponding standard unit costs in euros. Health outcomes will be evaluated by assessing patient-reported quality of life through the validated questionnaires EuroQol 5 Dimensions (EQ5D). Quality adjusted life years (QALYs) will be derived from the EQ5D outcomes. Costs per QALY will be compared per treatment arm to compare cost-effectiveness.
Time frame: At 18 months follow-up
Patient reported quality of life
Measured by the validated questionnaire EuroQol 5 Dimensions (EQ5D). The EQ5D evaluates a patient's health accross five core dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) giving it a score of 1 (no problems) to 5 (extreme problems).
Time frame: At 30 days, 12- and 18-months follow-up
Intention to treat analysis without 30-day adverse event exclusion
The primary and secondary endpoints will be evaluated in all patients who were initially included at time of ACS diagnosis based on their randomized treatment, i.e., independent of adverse events in the first 30 days after ACS diagnosis and irrespective of received treatment.
Time frame: At 12- and 18-months follow-up
Outcome differences in bleeding events
To compare bleeding events (%) in both treatment arms.
Time frame: At 18-months follow-up
Relation between patients ethnic background (self-reported) and clinical presentation
Does self-defined ethnic background impact the incidence of clinical presentation (STEMI/NSTEMI/unstable angina). For example, is there an association between non-Western European ethnic background and the type of clinical presentation (STEMI/NSTEMI/unstable angina).
Time frame: At 18-months follow-up
Relation between patients highest obtained education level and clinical outcome
Is there a negative correlation between the highest obtained educational level and the incidence of the primary and secondary endpoints (%)
Time frame: At 18-months follow-up
Correlation between Non-enrollers and enrollers
Clinical outcome (based on primary and secondary endpoints) of patients who were not enrolled vs patients who were enrolled in the study based on data from medical records
Time frame: 18 months
Outcome differences diabetes mellitus
Differences in primary and secondary endpoints (%) of diabetic vs non-diabetic participants.
Time frame: At 18 months follow-up
Outcome differences gender
Differences in primary and secondary endpoints (%) of male vs female participants.
Time frame: At 18 months follow-up
Outcome differences elderly
Differences in primary and secondary endpoints (%) of elderly (\>= 75 years) vs non-elderly participants.
Time frame: At 18 months follow-up
Outcome differences invasive acute coronary syndrome treatment
Differences in primary and secondary endpoints (%) of participants treated with percutaneous coronary intervention vs non-invasively-treated.
Time frame: At 18 months follow-up
Outcome differences multivessel disease
Differences in primary and secondary endpoints (%) of participants treated with multivessel percutaneous intervention vs non treated with mutlivessel percutaneous intervention.
Time frame: At 18 months follow-up
Outcome differences acute coronary syndrome type
Differences in primary and secondary endpoints (%) of participants with acute myocardial infarction vs unstable angina.
Time frame: At 18 months follow-up
Relation between patients ethnic background (self-reported) and dual antiplatelet use
Does self-reported ethnic background impact the incidence of dual antiplatelet use (therapy adherence). For example, does non-Western European ethnic background have an association with higher therapy adherence? This will be measured by self-reported adherence and pharmacist's records of dual antiplatelet therapy pick up.
Time frame: At 18 months
Relation between patients ethnic background (self-reported) and clinical outcome
Does ethnic background impact the incidence of the clinical outcome (primary and secondary endpoints). For example, is there an association between non-Western European ethnic background and lower rates of the primary or secondary endpoints.
Time frame: At 18 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.
Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 36 months is below that.
Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medisch Spectrum Twente